Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

Purpose: Results from the LAUNCH trial suggest transarterial chemoembolization (TACE) in combination with lenvatinib is significantly more effective than lenvatinib as a first-line treatment option for advanced hepatocellular carcinoma (HCC). However, the cost of TACE is substantial. This study comp...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Ying, Lin, Wangchun, Cai, Zhongjie, Huang, Yufan, You, Maojin, Lei, Meisheng, Chen, Ruijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512705/
https://www.ncbi.nlm.nih.gov/pubmed/37745079
http://dx.doi.org/10.3389/fphar.2023.1219694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512705/
https://www.ncbi.nlm.nih.gov/pubmed/37745079
http://dx.doi.org/10.3389/fphar.2023.1219694

Ejemplares similares